AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 12 min read$ALKS

Hopkinson Craig C. sold $375K of ALKS

Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 9,000 shares of Alkermes plc. (ALKS) at $41.67 ($0.38M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hopkinson Craig C.
Published Jun 1, 2026, 11:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALKS
Neutral
high confidence
Mentioned
$ALKS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

Absent any accompanying company-specific news (earnings, trial results, approvals, deals, litigation), the disclosure mainly informs positioning/sentiment rather than fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this specific Form 4 alone is unlikely to drive a durable repricing.

03

What to watch

10b5-1 plans are pre-scheduled and often driven by liquidity/tax planning, reducing the signal-to-noise of insider selling.

Relevance 6/10Novelty 2/10Timing: Filed same day (2026-06-01) as the sale; potential intraday sentiment check.

Background

The filing is an SEC Form 4 for an Alkermes executive (EVP R&D, Chief Medical Officer) reporting an open-market sale executed under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$ALKSNeutralHigh confidence
Context

Alkermes (ALKS) disclosed an officer open-market sale: 9,000 shares sold on 2026-06-01 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited and quickly mean-reverting.

Evidence & confidence

Form 4 insider sales under a pre-arranged 10b5-1 plan typically have limited informational content versus buys tied to new events.

Market effects

Sector

Minimal; single-company insider transaction without accompanying guidance/clinical/regulatory updates.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the sale volume is unusually large relative to prior patterns, traders could briefly interpret it as caution—even with a 10b5-1 plan.

Key entities

  • issuer
    Alkermes plc

    Subject of the insider transaction disclosure (Form 4) reporting an officer sale of ALKS shares.

  • insider
    Hopkinson Craig C.

    EVP R&D and Chief Medical Officer who sold 9,000 shares on 2026-06-01 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALKS insider trading history →

Related articles

AUG 28
$ALKSMedAI 8/10

Phase 2 Data on Investigational Narcolepsy Drug Published

Alkermes' investigational narcolepsy drug alixorexton showed statistically significant improvements in wakefulness and cataplexy in a phase 2 study. The treatment was well-tolerated and improved patient-reported outcomes. The company has initiated a phase 3 program based on these results, according to the company.

sleepreviewmag.com2 min
AUG 27
$ALKSMedAI 9/10

Did Positive Vibrance-1 Data and Brilliance Phase 3 Launch Just Shift Alkermes' (ALKS) Investment Narrative?

Alkermes (ALKS) reported positive Phase 2 data for alixorexton in narcolepsy, leading to a global Phase 3 trial launch. The data, published in The Lancet Neurology, showed significant improvements in wakefulness and safety. The company aims for $2.3B revenue by 2029, with analysts projecting up to $2.8B. Success hinges on Phase 3 trial outcomes.

simplywall.st2 min
AUG 25
$ALKSMedAI 8/10

Alkermes plc: The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

Alkermes (ALKS) announced positive phase 2 study results for alixorexton in adults with narcolepsy type 1, published in The Lancet Neurology. The study showed statistically significant improvements in wakefulness and cataplexy, with all doses well-tolerated. Alkermes has initiated phase 3 trials for alixorexton in narcolepsy types 1 and 2.

finanznachrichten.de2 min